At Novo Nordisk, patient safety is a top priority. As the sole manufacturer of FDA-approved medicines containing semaglutides, Novo Nordisk is deeply concerned by companies promoting and selling non-FDA-approved knock-off drugs that claim to contain the same “semaglutide.” As a result of the concerning dynamics in the marketplace, Novo Nordisk is committed to raising awareness of the dangers of compounded or knock-off “semaglutide”. Here are three important facts to know if you or someone you care for is considering an unapproved, compounded product.
Latest Posts
Partner News
An ROI Study of Modern Health’s Adaptive Care Model for Mental Health Prevention and Treatment
Organizations often focus on responding to the most urgent mental health needs. Modern Health’s ROI ...
Read More
Partner News
Espresa: Wellbeing that Works – How Flexible Benefits Drive Real Engagement
Today’s workforce is stretched thin—balancing caregiving, health, and daily life before the workday begins. It’s ...
Read More
Partner News
WTW: Employer Role in Preventing Cardiovascular Disease
Mortality from heart disease declined in the US between 1980 and 2010 due to the ...
Read More